Product Code: GMDHC9904IDB
Summary:
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Benign Prostatic Hyperplasia - Pipeline Review, H2 2017, provides an overview of the Benign Prostatic Hyperplasia (Male Health) pipeline landscape.
Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate, a small gland that encircles the urethra in males and produces a fluid that makes up part of semen. Symptoms include decreased strength of the urine stream, dribbling after urination, pain during urination, waking at night to urinate, difficulty starting a urine stream. Treatment options for BPH include surgery and medications.
Report Highlights:
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Benign Prostatic Hyperplasia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Benign Prostatic Hyperplasia (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Benign Prostatic Hyperplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 9, 5, 5, 1, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.
Benign Prostatic Hyperplasia (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Benign Prostatic Hyperplasia (Male Health).
- The pipeline guide reviews pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Benign Prostatic Hyperplasia (Male Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Benign Prostatic Hyperplasia (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health)
Reasons to buy:
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Benign Prostatic Hyperplasia (Male Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia (Male Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Table of Contents
- List of Tables
- List of Figures
- Introduction
- Global Markets Direct Report Coverage
- Benign Prostatic Hyperplasia - Overview
- Benign Prostatic Hyperplasia - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Benign Prostatic Hyperplasia - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Benign Prostatic Hyperplasia - Companies Involved in Therapeutics Development
- Addex Therapeutics Ltd
- AndroScience Corp
- Aphios Corp
- Astellas Pharma Inc
- BCWorld Pharm Co Ltd
- Biolab Farmaceutica Ltda
- Chong Kun Dang Pharmaceutical Corp
- Curadis GmbH
- Dongkook Pharmaceutical Co Ltd
- GL Pharm Tech Corp
- Health Ever Bio-Tech Co Ltd
- Jeil Pharmaceutical Co Ltd
- MEI Pharma Inc
- Meiji Seika Pharma Co Ltd
- Mezzion Pharma Co Ltd
- Nymox Pharmaceutical Corp
- Ono Pharmaceutical Co Ltd
- OPKO Health Inc
- SK Chemicals Co Ltd
- Sophiris Bio Inc
- Sun Pharma Advanced Research Company Ltd
- The Female Health Company
- XuanZhu Pharma Co Ltd
- Yungjin Pharm Co Ltd
- Yuyu Pharma Inc
- Benign Prostatic Hyperplasia - Drug Profiles
- (alfuzosin hydrochloride ER + tadalafil) - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (dutasteride + tadalafil) - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (solifenacin + tamsulosin) - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (tadalafil + tamsulosin hydrochloride) - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- ADX-68692 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- ASC-JM.X2 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- AUS-131 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- BCWPE-004 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- BL-214 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- CR-1447 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- fexapotide triflutate - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- KKM-1202 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- L-1AD3 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- MCS-2 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- NCE-403 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- ONO-8430506 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- S-0131632 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- sirolimus - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Sperol - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- talaporfin sodium - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- tamsulosin hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- tamsulosin hydrochloride CR - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- tamsulosin hydrochloride DR - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- tamsulosin SR - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- tertomotide - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- topsalysin - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- TT-701 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- udenafil - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- XZP-5849 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- YBH-1603 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- YOB-1604 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- YY-201 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Benign Prostatic Hyperplasia - Dormant Projects
- Benign Prostatic Hyperplasia - Discontinued Products
- Benign Prostatic Hyperplasia - Product Development Milestones
- Featured News & Press Releases
- Nov 07, 2017: Nymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological Association New York Section Annual Meeting in Havana
- Oct 13, 2017: Nymox Reports on Symposium, Panel Discussion with Abstract on Fexapotide at American Urological Association Northeast Sectional Annual Meeting in Savannah
- Oct 10, 2017: Nymox Reports on Symposium and Panel Discussion on Fexapotide at American Urological Association Northeast Sectional Annual Meeting in Savannah October 12
- Sep 25, 2017: Nymox Announces October 12 Symposium for Company's BPH Drug at American Urological Association Meeting
- Sep 15, 2017: Mayne Pharma Adds Urorec (silodosin) Capsules to Its Australian Portfolio
- Sep 14, 2017: Nymox Announces New Symposium for Companys BPH Drug at American Urological Association Meeting October 5
- Sep 14, 2017: Nymox Announces Validation by the European Member States of European Marketing Authorization Application for Fexapotide Triflutate for Benign Prostatic Hyperplasia
- Aug 07, 2017: Nymox Announces Symposium for Company's BPH Drug at American Urological Association Meeting in September
- May 31, 2017: Sexual Function Improves in First-Line Patients Given Fexapotide Treatment in Nymox U.S. BPH Long-Term Clinical Trials
- May 08, 2017: NYMOX Files For Approval of First In Class Prostate Drug in Europe
- May 03, 2017: NYMOX Files For Marketing Approval For Fexapotide Triflutate in Europe
- Mar 29, 2017: Nymox Provides Update on Fexapotide Development
- Dec 14, 2016: CFDA Granted Approval forPhase I/II/III Clinical Trials of Sihuan Pharmaceutical's Internally Developed Innovative Patented New Drug - Fadanafil
- Nov 29, 2016: Nymox Reports Additional Positive Results From Completed Fexapotide BPH Phase 3 Studies Showing Significant Early Response and First-Line Efficacy
- Sep 20, 2016: Addex collaborators publish new data on negative allosteric modulator ADX68692
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
List of Tables
- Number of Products under Development for Benign Prostatic Hyperplasia, H2 2017
- Number of Products under Development by Companies, H2 2017
- Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
- Number of Products under Development by Universities/Institutes, H2 2017
- Products under Development by Companies, H2 2017
- Products under Development by Companies, H2 2017 (Contd..1), H2 2017
- Products under Development by Universities/Institutes, H2 2017
- Number of Products by Stage and Target, H2 2017
- Number of Products by Stage and Mechanism of Action, H2 2017
- Number of Products by Stage and Route of Administration, H2 2017
- Number of Products by Stage and Molecule Type, H2 2017
- Benign Prostatic Hyperplasia - Pipeline by Addex Therapeutics Ltd, H2 2017
- Benign Prostatic Hyperplasia - Pipeline by AndroScience Corp, H2 2017
- Benign Prostatic Hyperplasia - Pipeline by Aphios Corp, H2 2017
- Benign Prostatic Hyperplasia - Pipeline by Astellas Pharma Inc, H2 2017
- Benign Prostatic Hyperplasia - Pipeline by BCWorld Pharm Co Ltd, H2 2017
- Benign Prostatic Hyperplasia - Pipeline by Biolab Farmaceutica Ltda, H2 2017
- Benign Prostatic Hyperplasia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017
- Benign Prostatic Hyperplasia - Pipeline by Curadis GmbH, H2 2017
- Benign Prostatic Hyperplasia - Pipeline by Dongkook Pharmaceutical Co Ltd, H2 2017
- Benign Prostatic Hyperplasia - Pipeline by GL Pharm Tech Corp, H2 2017
- Benign Prostatic Hyperplasia - Pipeline by Health Ever Bio-Tech Co Ltd, H2 2017
- Benign Prostatic Hyperplasia - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2017
- Benign Prostatic Hyperplasia - Pipeline by MEI Pharma Inc, H2 2017
- Benign Prostatic Hyperplasia - Pipeline by Meiji Seika Pharma Co Ltd, H2 2017
- Benign Prostatic Hyperplasia - Pipeline by Mezzion Pharma Co Ltd, H2 2017
- Benign Prostatic Hyperplasia - Pipeline by Nymox Pharmaceutical Corp, H2 2017
- Benign Prostatic Hyperplasia - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
- Benign Prostatic Hyperplasia - Pipeline by OPKO Health Inc, H2 2017
- Benign Prostatic Hyperplasia - Pipeline by SK Chemicals Co Ltd, H2 2017
- Benign Prostatic Hyperplasia - Pipeline by Sophiris Bio Inc, H2 2017
- Benign Prostatic Hyperplasia - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017
- Benign Prostatic Hyperplasia - Pipeline by The Female Health Company, H2 2017
- Benign Prostatic Hyperplasia - Pipeline by XuanZhu Pharma Co Ltd, H2 2017
- Benign Prostatic Hyperplasia - Pipeline by Yungjin Pharm Co Ltd, H2 2017
- Benign Prostatic Hyperplasia - Pipeline by Yuyu Pharma Inc, H2 2017
- Benign Prostatic Hyperplasia - Dormant Projects, H2 2017
- Benign Prostatic Hyperplasia - Dormant Projects, H2 2017 (Contd..1), H2 2017
- Benign Prostatic Hyperplasia - Dormant Projects, H2 2017 (Contd..2), H2 2017
- Benign Prostatic Hyperplasia - Discontinued Products, H2 2017
List of Figures
- Number of Products under Development for Benign Prostatic Hyperplasia, H2 2017
- Number of Products under Development by Companies, H2 2017
- Number of Products under Development by Universities/Institutes, H2 2017
- Number of Products by Top 10 Targets, H2 2017
- Number of Products by Stage and Top 10 Targets, H2 2017
- Number of Products by Top 10 Mechanism of Actions, H2 2017
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
- Number of Products by Top 10 Routes of Administration, H2 2017
- Number of Products by Stage and Top 10 Routes of Administration, H2 2017
- Number of Products by Molecule Types, H2 2017
- Number of Products by Stage and Molecule Types, H2 2017
